<![CDATA[EU/3/17/1876 (Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide)

<![CDATA[EU/3/17/1876 (Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - TMC Pharma Services Ltd]]> 1440 Copyright: (C) European Commission en-gb Tue, 23 May 2017 12:05:00 +0000 http://ec.europa.eu/health/documents/community-register/html/o1876.htm <![CDATA[EU/3/17/1876 (Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - TMC Pharma Services Ltd]]> http://ec.europa.eu/health/documents/community-register/images/logo_en.gif http://ec.europa.eu/health/documents/community-register/html/o1876.htm 144 100 Orphan designation - Commission Decision (2017)3609 of Tue, 23 May 2017 New documents http://ec.europa.eu/health/documents/community-register/html/o1876.htm#proc137945 http://ec.europa.eu/health/documents/community-register/html/o1876.htm#proc137945 Tue, 23 May 2017 12:05:00 +0000